Comprehensive TRT Panel: Every Lab Test You Need Before and During Testosterone Therapy

Why a Comprehensive Panel Beats a Single Testosterone Number

Running only a total testosterone level before starting TRT is like checking only your tire pressure before a cross-country drive. The number tells you something, but it misses the information that actually determines what you should do next. A full panel gives your prescribing physician the data needed to choose the right starting dose, identify contraindications, and catch the two or three adverse changes that TRT reliably produces in a subset of men.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism specifies that diagnosis requires "both a total testosterone level below the normal range and symptoms consistent with androgen deficiency," and explicitly calls for repeat measurement with a morning fasting sample before any prescription is written [1]. That same guideline lists the specific tests that must accompany testosterone measurement at baseline, including LH, FSH, and prolactin when secondary hypogonadism is suspected.

Skipping any biomarker in the panel does not make TRT safer. It only delays the discovery of a problem that will eventually surface on a lab report.

Total Testosterone: Morning Draw, Correct Reference Range

Total testosterone is the anchor measurement. Labs report it in ng/dL in the United States, and the normal adult male range from most certified labs runs from roughly 300 to 1 to 000 ng/dL, though the Endocrine Society places the lower threshold of normal at approximately 264 ng/dL based on the Framingham Heart Study male cohort [1]. On TRT, the clinical target for most men using injectable testosterone cypionate or enanthate is a mid-cycle trough of 500 to 900 ng/dL, drawn 4 to 5 days after a twice-weekly injection or just before the next weekly injection.

Two draws matter. The FDA label for testosterone products and the Endocrine Society both require two separate low morning values (drawn between 7 and 10 a.m.) to confirm hypogonadism before initiating therapy [1, 2]. A single borderline result is not a prescription.

Timing of the draw relative to the last injection is often overlooked. A patient who draws blood the day after an injection will show a peak value that can reach 1 to 400 ng/dL, which looks alarming but is pharmacokinetically normal. A draw at the wrong time produces a number that is clinically meaningless and leads to unnecessary dose adjustments.

Free Testosterone: The Number That Often Explains Symptoms

Roughly 44 to 65 percent of circulating testosterone binds tightly to sex hormone-binding globulin (SHBG) and is biologically unavailable to tissues. Another 30 to 40 percent binds loosely to albumin. Only 2 to 3 percent circulates as free (unbound) testosterone [3]. Free testosterone is the fraction that crosses cell membranes and activates androgen receptors in muscle, bone, brain, and sexual tissue.

A man can present with a total testosterone of 420 ng/dL and feel profoundly symptomatic if his SHBG is 70 nmol/L, because his free testosterone may sit at 6 pg/mL, well below the 15 pg/mL threshold most labs use as a lower reference. The same total testosterone with SHBG of 20 nmol/L yields a free testosterone near 20 pg/mL, which is functionally normal.

Calculating free testosterone. The Vermeulen formula, which uses total testosterone, SHBG, and albumin (assumed constant at 4.3 g/dL), generates a calculated free testosterone that correlates well with equilibrium dialysis in most clinical situations [4]. The online calculator maintained by the Hormonology and Endocrinology groups at many academic centers uses this formula. Equilibrium dialysis is the gold-standard measurement but costs more and is rarely needed outside research settings.

Clinical target. Most TRT-experienced physicians aim for a calculated free testosterone between 15 and 25 pg/mL at trough. Values above 30 pg/mL at trough suggest the dose is too high or SHBG is suppressed enough to warrant a dose reduction.

SHBG: The Variable That Changes Everything

SHBG is a glycoprotein produced by the liver. High SHBG (above 50 nmol/L) lowers free testosterone for a given total testosterone. Low SHBG (below 18 nmol/L) means a larger fraction is free but also cleared faster, which shortens the effective half-life of injected testosterone and may require more frequent dosing intervals.

Conditions that raise SHBG include aging, hyperthyroidism, liver cirrhosis, and use of certain anticonvulsants. Conditions that lower SHBG include obesity, insulin resistance, hypothyroidism, and use of anabolic androgens [5]. A baseline SHBG value therefore contextualizes every subsequent total testosterone reading and informs whether weekly or twice-weekly injections will maintain more stable free testosterone levels.

Estradiol: Sensitive Assay Only

Testosterone aromatizes to estradiol (E2) in adipose tissue, the brain, and testes. Some elevation of estradiol on TRT is expected and is physiologically appropriate. E2 contributes to bone mineral density, cardiovascular health, sexual function, and mood in men [6]. The goal is not zero estradiol. The goal is a ratio and an absolute level that avoids both extremes.

Estradiol excess (E2 above approximately 40, 50 pg/mL in most men on TRT) may cause water retention, gynecomastia, and mood instability. Estradiol deficiency (E2 below 20 pg/mL, commonly caused by over-use of aromatase inhibitors such as anastrozole) is associated with joint pain, low libido, depressed mood, bone loss, and poor cardiovascular markers.

The assay matters enormously. Standard immunoassay estradiol tests, sometimes labeled "E2 total" or "estradiol (standard)," were validated for the high estradiol levels found in women and are notoriously inaccurate at the lower male range. They can overestimate male E2 by 30 to 50 percent [7]. The correct test is the sensitive estradiol assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS), sometimes listed as "estradiol, sensitive" or "estradiol, ultrasensitive" on lab requisition forms. Quest Diagnostics lists this as test code 30289, and LabCorp lists it as test number 140244.

Always order the sensitive assay. The standard assay will mislead you.

LH and FSH: Baseline Diagnosis, Not Ongoing Monitoring

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are drawn once, at baseline, before starting TRT. Their purpose is to distinguish primary from secondary hypogonadism.

• Primary hypogonadism (testicular failure): high LH and FSH with low testosterone. Causes include Klinefelter syndrome, orchitis, radiation, or chemotherapy.
• Secondary hypogonadism (hypothalamic or pituitary failure): low or normal LH and FSH with low testosterone. Causes include pituitary adenoma, hyperprolactinemia, opioid use, or idiopathic hypogonadotropic hypogonadism.

If LH and FSH are both low and the patient is under 40, prolactin and an MRI of the pituitary may be warranted before starting TRT, as the Endocrine Society guideline recommends [1]. Treating secondary hypogonadism due to a prolactinoma with testosterone alone addresses the symptom but not the tumor.

Once TRT begins, LH and FSH will drop to near zero in almost all men within a few weeks. Rechecking them after starting testosterone adds no clinical value and does not need to be part of ongoing monitoring panels.

CBC with Differential: Watching for Polycythemia

Testosterone stimulates erythropoiesis through EPO-dependent and EPO-independent pathways. Red blood cell production increases, hemoglobin rises, and hematocrit climbs. This is the most common adverse lab change on TRT. It occurs in roughly 5 to 7 percent of men on physiologic replacement doses, but the rate rises substantially with higher doses, older age, sleep apnea, and smoking [8].

The hematocrit threshold is 54 percent. The Endocrine Society guideline and the AUA both specify that TRT should be withheld or the dose reduced when hematocrit exceeds 54%, because the viscosity of blood at that level meaningfully increases the risk of venous thromboembolism [1, 9]. A hematocrit between 50 and 54 percent warrants close monitoring and review of dose and injection frequency. Switching from weekly to twice-weekly injections (same total weekly dose) reduces peak testosterone and peak erythropoietic stimulus, which often stabilizes hematocrit in the 50 to 52 percent range.

Draw schedule for CBC. Check at baseline, at 6 to 8 weeks, at 3 to 6 months, and then annually once stable. Men with baseline hematocrit above 48 percent or with known sleep apnea deserve more frequent checks.

PSA: Prostate Monitoring Before and During TRT

Testosterone does not cause prostate cancer, but it can accelerate the growth of pre-existing androgen-sensitive prostate cancer. A PSA drawn before starting TRT establishes the individual's baseline and provides a reference point for future comparison.

The AUA's 2018 testosterone deficiency guideline recommends PSA at baseline and at 3 to 6 months after initiation [9]. A rise of more than 1.4 ng/mL above baseline within the first 12 months, or a PSA above 4.0 ng/mL at any point, warrants urologic referral before continuing TRT. Men with a prior prostate cancer diagnosis or an untreated PSA above 4.0 ng/mL are generally excluded from TRT until urologically evaluated.

A digital rectal exam (DRE) is still recommended by the AUA at baseline for men over 40, though its sensitivity for identifying TRT-relevant prostate pathology is limited. PSA remains the primary screening tool.

CMP: Liver, Kidney, and Glucose

A comprehensive metabolic panel (CMP) at baseline captures fasting glucose, creatinine, estimated GFR, and liver enzymes (AST, ALT, ALP, bilirubin, total protein, albumin).

Liver enzymes. Oral 17-alpha-alkylated androgens such as methyltestosterone are hepatotoxic. Injectable testosterone cypionate, testosterone enanthate, subcutaneous testosterone pellets, and transdermal testosterone gels are not hepatotoxic at physiologic doses [10]. Mildly elevated transaminases on injectable TRT are usually explained by muscle breakdown (skeletal muscle AST) rather than hepatic injury. Still, a baseline CMP allows differentiation. A CMP should be rechecked at 6 months and then annually.

Glucose and kidney function. Testosterone improves insulin sensitivity in some hypogonadal men; fasting glucose often improves. Creatinine may rise slightly due to increased lean muscle mass, which increases creatinine production. A rise in creatinine that is disproportionate to muscle mass gain should prompt nephrology review.

Lipid Panel: TRT's Mixed Effect on Cholesterol

Testosterone therapy has a modestly unfavorable effect on HDL cholesterol in some men, reducing it by an average of 5 to 8 percent in short-term studies, while effects on LDL are variable [11]. Total cholesterol and triglycerides often improve, partly as a secondary effect of reduced body fat and improved insulin sensitivity over time.

A fasting lipid panel should be drawn at baseline and at 6 months. If the HDL decline is significant (below 35 mg/dL) and cardiovascular risk is high, the prescribing physician may adjust dose or route of delivery, since transdermal testosterone has a less pronounced HDL-lowering effect compared to injections in some trials.

Thyroid Screen: TSH at Baseline

Hypothyroidism raises SHBG and can produce symptoms (fatigue, weight gain, low libido, cognitive fog) that overlap almost perfectly with hypogonadism. A TSH drawn at baseline catches this confounder. Men whose TSH is above 4.5 mIU/L may need thyroid treatment before or alongside TRT, because normalizing thyroid function sometimes resolves androgen deficiency symptoms without requiring testosterone at all.

TSH does not need to be repeated at every TRT follow-up visit unless symptoms suggest thyroid dysfunction.

Prolactin: Drawn Once, When Indicated

Prolactin is drawn at baseline in men with secondary hypogonadism (low LH, low FSH, low testosterone) and in any man presenting with galactorrhea, visual field defects, or headaches. Hyperprolactinemia suppresses GnRH pulsatility, leading to secondary hypogonadism. Prolactin-secreting adenomas (prolactinomas) are the most common pituitary tumor and are treated with dopamine agonists such as cabergoline, not with testosterone [1].

Routine prolactin measurement in every man with low testosterone is not required by current guidelines. Check it when the clinical picture points toward pituitary disease.

Complete TRT Panel Reference Table

The following framework summarizes which tests to draw at each phase of TRT, based on current Endocrine Society and AUA guidance plus HealthRX clinical protocol.

| Biomarker | Baseline | 6, 8 Weeks | 3, 6 Months | Annual | |---|---|---|---|---| | Total testosterone (AM) | Yes | Yes | Yes | Yes | | Free testosterone (calculated) | Yes | Yes | Yes | Yes | | SHBG | Yes | Yes | Yes | Yes | | Estradiol, sensitive (LC-MS/MS) | Yes | Yes | Yes | Yes | | LH, FSH | Yes | No | No | No | | Prolactin (if indicated) | Yes | No | No | No | | CBC with differential | Yes | Yes | Yes | Yes | | PSA (men 40+) | Yes | Yes | Yes | Yes | | CMP | Yes | No | Yes | Yes | | Fasting lipid panel | Yes | No | Yes | Yes | | TSH | Yes | No | No | If symptomatic |

How to Read Your Results: Red Flags at Each Marker

Getting the results is only useful if you know which numbers require action before the next scheduled follow-up. Here are the thresholds that should prompt a call to your prescribing physician before any scheduled appointment.

Hematocrit above 54%. Stop TRT until you speak with your physician. Do not donate blood without medical supervision as a first-line intervention; the underlying dose or frequency issue needs to be addressed.

PSA rise of more than 1.4 ng/mL from baseline within 12 months. Request urologic evaluation. Do not simply continue TRT and recheck in 3 months without urologist input.

Estradiol (sensitive) above 60 pg/mL with symptomatic gynecomastia. Aromatase inhibitor use or dose reduction may be warranted, but self-prescribing anastrozole without confirmed lab elevation is a common and preventable cause of estradiol crash.

Total testosterone trough above 1 to 100 ng/dL. Dose or frequency reduction is appropriate. Supraphysiologic peaks accelerate erythropoiesis and increase cardiovascular strain.

ALT or AST above three times the upper limit of normal. Rule out other hepatic causes. Injectable testosterone at physiologic doses does not cause this degree of elevation; concurrent hepatotoxin (alcohol, DILI from another medication) is likely.

Timing Your Draw: The Detail Most Patients Get Wrong

For men on testosterone cypionate or enanthate injections, the draw should occur at trough, meaning just before the next scheduled injection. If injecting weekly, draw on day 6 or 7. If injecting twice weekly, draw on the morning of the injection day before administering the dose.

For men on transdermal testosterone gel or cream, the draw should occur 2 to 4 hours after applying the morning dose, which captures approximate peak absorption for that route [2].

For men on testosterone pellets (subcutaneous), draw at 5 to 6 weeks post-insertion for peak confirmation, then at 4 to 5 months to assess trough before repeat pellet insertion.

Consistent timing across all follow-up draws is what makes trend analysis possible. A testosterone of 620 ng/dL drawn at trough and a testosterone of 620 ng/dL drawn at peak represent entirely different clinical situations.

Frequency of Monitoring After Dose Changes

Any change in dose, frequency, or delivery method restarts the monitoring clock. Draw a new 6 to 8 week follow-up panel after every protocol adjustment. Once a patient is stable for two consecutive follow-up panels without dose changes, annual monitoring is appropriate for most biomarkers, with hematocrit and PSA rechecked every 6 months in men over 50 or with elevated baseline cardiovascular risk.

The AUA 2018 guideline statement on testosterone deficiency notes: "Testosterone therapy should not be initiated until the diagnosis is confirmed by laboratory testing and a complete history and physical examination are performed" [9]. That principle extends to ongoing management: no dose change should be made without a corresponding lab draw.